Advanced Pancreatic Cancer
Advanced pancreatic cancer is a severe form of cancer that starts in the pancreas and has spread to other parts of the body. It often leads to significant symptoms and challenges in treatment.
PBP1510 for Advanced Pancreatic Cancer
We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have advanced or metastatic pancreatic cancer?
- Are you currently pregnant or breastfeeding?
- Have you had chemotherapy or radiation therapy in the last 2 weeks?
- Are you taking any medications that could affect your eligibility, like blood thinners or steroids?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Humanized Monoclonal Antibody
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hospital Universitario La Paz
Oncology
Chamartín, Spain
Hospital Universitario Miguel Servet
Oncology
Zaragoza, Spain
Sponsor: Prestige Biopharma Ltd
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.